VVUS - VIVUS, Inc.
| Previous Close | 0.6350 |
| Open | 0.6300 |
| Bid | 0.6200 x 900 |
| Ask | 0.6490 x 1000 |
| Day's Range | 0.6219 - 0.6484 |
| 52 Week Range | 0.3300 - 1.0200 |
| Volume | 397,968 |
| Avg. Volume | 861,885 |
| Market Cap | 66.063M |
| Beta | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3800 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
Market Realist•5 days agoA Look at Novo Nordisk’s Human Insulin and Obesity Business
In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.
- Zacks•11 days ago
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
- Associated Press•12 days ago
Vivus: 2Q Earnings Snapshot
The Campbell, California-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $15 million in the period. In the final minutes of trading on Tuesday, the ...
- GlobeNewswire•12 days ago
VIVUS Reports Second Quarter 2018 Financial Results
Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., Aug. 07, 2018-- VIVUS, Inc., a specialty pharmaceutical company committed to the development and commercialization of innovative therapies ...
- ACCESSWIRE•12 days ago
VIVUS, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / VIVUS, Inc. (NASDAQ: VVUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...
- GlobeNewswire•13 days ago
VIVUS Appoints Kenneth Suh as President
CAMPBELL, Calif., Aug. 06, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. Suh was President and CEO of Willow Biopharma Inc., ...
- GlobeNewswire•19 days ago
VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 7, 2018
CAMPBELL, Calif., July 31, 2018-- VIVUS, Inc. today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August ...
- Zacks•last month
VIVUS' PAH Candidate Data Positive in Early Stage Study
VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.
- Zacks•last month
VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session
VIVUS (VVUS) was a big mover last session, as the company saw its shares rise more than 10% on the day, amid huge volumes.
- GlobeNewswire•last month
VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106
-Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension-. CAMPBELL, Calif., July 10, 2018-- VIVUS, Inc., a biopharmaceutical ...
- InvestorPlace•2 months ago
3 Biotech Stocks Up in the Past Month on Industry Turnaround
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
- Benzinga•2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...
- Zacks•2 months ago
Can The Uptrend Continue for VIVUS (VVUS)?
Investors certainly have to be happy with VIVUS, Inc. (VVUS) and its short term performance
- GlobeNewswire•2 months ago
VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S. and Canadian rights to PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) from Janssen Pharmaceuticals, Inc. (Janssen) for $135 million. Concurrently, VIVUS completed its previously announced financing agreement with Athyrium Capital Management, L.P. (Athyrium). “The restructuring of a portion of our debt coupled with the acquisition of a cash flow generating asset, PANCREAZE, will move VIVUS towards our goal of becoming an operating profit generating specialty pharmaceutical company. The PANCREAZE transaction fits a well-defined strategy of acquiring assets utilizing VIVUS’ improving operational and financial discipline as a base platform,” said John Amos, Chief Executive Officer at VIVUS.
- Zacks•2 months ago
3 Biotech Stocks Up in the Past Month on Industry Turnaround
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
- ACCESSWIRE•3 months ago
Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks
Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.
- Zacks•3 months ago
VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher
VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
- Market Realist•3 months ago
Vivus Stock Rose 60% Last Week
Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.
- ACCESSWIRE•3 months ago
Biotech CEO Presents: Merck’s $500M Pain, Our Potential Gain
Synergy Pharma's valuation peaked after data suggested its CIC treatment could challenge Ironwood's Lizness; Vivus soared on potential to beat weight-loss drugs with significant adverse effects Bellus ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 Vivus Inc Earnings Call
- Zacks•3 months ago
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
- Associated Press•3 months ago
Vivus: 1Q Earnings Snapshot
The Campbell, California-based company said it had a loss of 10 cents per share. The biopharmaceutical company posted revenue of $11.9 million in the period. In the final minutes of trading on Tuesday, ...
